Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.